Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis

Klinika Oczna

Volumn 112, Issue 4-6, 2010, Pages 147-150

  Małgorzata, Figurska ^a   Jacek, Robaszkiewicz ^a   Joanna, Wierzbowska ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Pathogenesis; Ranibizumab; Safety; Vascular endothelial growth factors; Wet AMD

Indexed keywords

MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

DRUG EFFECT; EXUDATIVE MACULAR DEGENERATION; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMMUNOLOGY; INJECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITREOUS BODY;

ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 77958177027     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Gehrs KM, Anderson DH, Johnson LV et al.: Age-related macular degeneration - emerging pathogenetic and therapeutic concepts. Annals of Med 2006, 38(7), 450-471. (Pubitemid 44767496)
2. Roberts WG, Palade GE: Increased microvascular permability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995, 108, 2369-2379.
3. Aiello LP, Avery RL, Arrigg PG et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331(22), 1480-1487. (Pubitemid 24356306)
4. Aiello LP, Northrup JN, Keyt BA et al.: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113(12), 1538-1544.
5. Tobe T, Okamoto N, Vinores MA et al.: Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998, 39(1), 180-188. (Pubitemid 28040477)
6. Ozaki J, Seo MS, Ozaki KA et al.: Blockade of vascular endothelial growth factor receptor is sufficient to completely prevent retinal neovascularisation. Am J Pathol 2000, 156(2), 679-707.
7. Ferrara N, Gerber HP, Le Couter J: The biology of VEGF and ist receptors. Nat Med 2003, 9(6), 699-676.
8. Ferrara N, Damico L, Shams N et al.: Development of Ranibizumab an anti-vascular endothelial growth factor antigen binding fragment as therapy for neovascular age-related macular degeneration. Retina 2006, 26(8), 859-870. (Pubitemid 44547437)
9. Chen Y, Wiesmann C, Fuh G et al.: Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinitymatured Fab in complex with antigen. J Mol Biol 1999, 293(4), 865-881. (Pubitemid 29527672)
10. Presta LG, Chen H, O'Connor SJ et al.: Humanization of an antivascular endothelial growth factor monoclonal antibody for the theray of solid tumors and other disorders. Cancer Res 1997, 57(20), 4593-4599. (Pubitemid 27441066)
11. Keyt BA, Nguyen HV, Berleau LT et al.: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996, 271(10), 5638-5646.
12. Lowe J: RhuFav V2 inhibits VEGF-isoforms stimulated HUVEC proliferation. Ophthalmol Vis Sci 2003, 44(5), 1828-1829.
13. Gaudreault J, Reich ME, Arata A et al.: Ocular Pharmacokinetics and Antipermeability Effect of rhuFab V2 in Animals. Invest Ophthalmol Vis Sci 2003, 44(4), 3942-3943.
14. Krzystolik MG, Afshari MA, Adamis AP et al.: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002, 120(3), 338-346. (Pubitemid 34250056)
15. Carmeliet P, Ferreira V, Breier G et al.: Abnormal blood vessel development and lethality in embroys lacking a single VEGF allele. Nature 1996, 380(6573), 435-439. (Pubitemid 26102719)
16. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992, 267(16), 10931-10934.
17. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-Ill: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994, 308(6923), 235-246.
18. Rosenfeld PJ, Brown DM, Heier JS et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355, 1419-1431. (Pubitemid 44511557)
19. Brown DM, Kaiser PK, Michels M et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355, 1432-1444. (Pubitemid 44511558)